ClinicalTrials.gg
Enrolling by invitationNCT06168305GENOSS-MVUpdated Oct 6, 2025

Safety and Effectiveness of GENOSS® DES in Patients With Multivessel Coronary Artery Disease

An observational study in Percutaneous Coronary Intervention and Multivessel Coronary Artery Disease, sponsored by Genoss Co., Ltd.. Enrolling by invitation at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-10-06.

Sponsored by Genoss Co., Ltd. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1,000
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Coronary Artery Disease by Genoss Co., Ltd. — 6 open to participants now, 6 under way, none of them phase 3. Coronary Artery Disease · Genoss Co., Ltd..

Started
2023
with 1 other
Observational
6 of 10
5 open now
Registered
8th of 10
by date

Among the 10 studies in Coronary Artery Disease by Genoss Co., Ltd., this one is one of 2 that started in 2023, is one of 6 observational ones, and was the 8th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

6 of the 10 studies in Coronary Artery Disease by Genoss Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 19 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Coronary Artery Disease by Genoss Co., Ltd., or all of them as a file.
02

Study summary

The investigators intend to establish a multicenter prospective observational study by enrolling and tracking patients with multivessel coronary artery disease (MVCAD) using Genoss DES, a device manufactured with pure domestic technology. The study aims to evaluate the efficacy and safety of Genoss DES in MVCAD patients.

Read the detailed description

This study is a sponsor-driven clinical trial (SIT) that aims to enroll patients who have undergone treatment for multivessel coronary artery disease using Genoss stents. The study involves collecting data on the clinical and surgical processes of patients and tracking the occurrence of clinical events.

This prospective, multicenter observational study registers patients with acute coronary artery disease who have been treated with GENOSS stents at a total of 8 institutions.

As it is an observational study, the number of subjects is not separately calculated, but the plan is to recruit a total of 1,000 participants during the study registration period.

03

Conditions studied

  • Percutaneous Coronary Intervention
  • Multivessel Coronary Artery Disease
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with multivessel coronary artery disease (MVCAD) who underwent percutaneous coronary intervention using GENOSS® DES

Eligibility criteria

\<Inclusion Criteria>

  • Adults over 19 years of age
  • Subjects with multivessel coronary artery disease (MVCAD) (However, subject registration is possible even if the treatment area is restenosis or recurrent lesion, including new lesions)
  • Subjects who underwent percutaneous coronary intervention (PCI) with GENOSS® DES
  • Research subjects who agree to the research protocol and clinical follow-up plan, voluntarily decide to participate in this clinical study, and give written consent in the form.

(However, in the case of foreigners, only those who can speak Korean fluently and understand Korean documents such as the consent form are included.)

\<Exclusion Criteria>

  • Test subjects with known or to the following drugs or substances: heparin, aspirin, clopidogrel, sirolimus, contrast medium (however, even subjects with hypersensitivity to contrast medium can be controlled by and pheniramine) In this case, registration is possible, but if there is known anaphylaxis, it is excluded)
  • When balloon angioplasty is performed on a stenotic area, the balloon cannot be expanded.
  • Those whose remaining is less than 1 year
  • Expecting to become pregnant, pregnant or lactating woman
  • The patient was admitted to the hospital due to cardiogenic shock and was predicted to have a low chance of survival based on medical judgment.

Subject

  • If the researcher determines that the product is not suitable for this clinical study or may increase the risks associated with participation in the study.
  • Foreigners who cannot speak Korean fluently and have difficulty understanding Korean documents
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • GENOSS® DES Sirolimus Eluting Coronary Stent System / B03300.20, class [4]

    Patients with multivessel coronary artery disease (MVCAD) who underwent percutaneous coronary intervention using GENOSS® DES

    Device: GENOSS® DES Sirolimus Eluting Coronary Stent System

Interventions

  • DeviceGENOSS® DES Sirolimus Eluting Coronary Stent System

    The GENOSS® DES is L-605 cobalt chromium (CoCr) platform with a strut thickness of 70µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.

06

What researchers measure

Primary outcomes

  1. Target Lesion Failure (TLF)

    The composite end point of cardiac death, TV-MI (target vessel-MI), and TLR (target lesion revascularization)

    Time frame: at 12 months after the procedure

Secondary outcomes

  1. Major adverse cardiac events (MACE)

    The composite end point of death, myocardial infarction, target lesion revascularization

    Time frame: at 12 months after the procedure

  2. Cardiac death

    Time frame: at 12 months after the procedure

  3. Non-cardiac death

    Time frame: at 12 months after the procedure

  4. TV-MI (target vessel-myocardial infarction)

    Time frame: at 12 months after the procedure

  5. Non-target vessel myocardial infarction

    Time frame: at 12 months after the procedure

  6. ID-TVR (ischemia-driven target vessel revascularization)

    Time frame: at 12 months after the procedure

  7. Non-ischemia driven target vessel revascularization

    Time frame: at 12 months after the procedure

  8. Incidence rate of acute stent thrombosis within 24 hours, subacute stent thrombosis within 30 days, and late stent thrombosis at 1 year

    Acute (within 24 hours), subacute (within 30 days), late (within 1 year)

    Time frame: within 24 hours, 30 days, 1 year

  9. Device success

    The clinical device is successfully delivered to the target lesion, inflated normally, and recovered intact.

    Time frame: during the procedure

  10. Procedure success

    When the final residual lesion stenosis is less than 50% using any surgical method, and there is no post-procedural death, myocardial infarction, or revascularization during the hospitalization period.

    Time frame: during the hospitalization period (up to 3 days)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Feb 2028, 51 months after the start.

Of 125 industry-sponsored observational studies under Coronary Artery Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 51 months is above that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2023
First posted
Dec 13, 2023
StartActual
Nov 15, 2023
Primary completionEst.
Feb 28, 2028
CompletionEst.
Feb 28, 2028
Last update
Oct 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06168305
Lead sponsor
Genoss Co., Ltd.
Responsible party
Sponsor
First posted
Dec 13, 2023
Start date
Nov 15, 2023
Primary completion
Feb 28, 2028 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Oct 6, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion